Tricyclic benzimidazoles as potent poly(ADP-ribose) polymerase-1 inhibitors

Journal of Medicinal Chemistry

Volumn 46, Issue 2, 2003, Pages 210-213

  Skalitzky, Donald J ^a   Marakovits, Joseph T ^a   Maegley, Karen A ^a   Ekker, Anne ^a   Yu, Xiao Hong ^a   Hostomsky, Zdenek ^a   Webber, Stephen E ^a,b   Eastman, Brian W ^a,c   Almassy, Robert ^a,d   Li, Jianke ^a   Curtin, Nicola J ^e   Newell, David R ^e   Calvert, A Hilary ^e   Griffin, Roger J ^e   Golding, Bernard T ^e  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c Merck Laboratories   (United States)

^d Quorex Pharmaceuticals   (United States)

^e NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

8 HYDROXY 2 METHYL 4(3H) QUINAZOLINONE; ADENOSINE DIPHOSPHATE RIBOSE; BENZIMIDAZOLE DERIVATIVE; DNA; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NU 1085; PD 128763; QUINAZOLINE DERIVATIVE; TEMOZOLOMIDE; TOPOTECAN; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL REACTION; DNA DAMAGE; DRUG POTENTIATION; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL;

ANTINEOPLASTIC AGENTS; BENZIMIDAZOLES; BINDING SITES; CELL LINE; CRYSTALLOGRAPHY, X-RAY; DACARBAZINE; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; MODELS, MOLECULAR; POLY(ADP-RIBOSE) POLYMERASES; PRODRUGS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TOPOTECAN;

EID: 0037448385     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0255769     Document Type: Article

References (21)

1. From DNA Damage and Stress Signaling to Cell Death: Poly ADP-ribosylation Reactions; de Murcia, G., Shall, S., Eds; Oxford University Press: Oxford, 2000. Cell Death: The Role of PARP.; Szabo, C., Ed.; CRC Press: Boca Raton, Fl, 2000 and references therein.
2. From DNA Damage and Stress Signaling to Cell Death: Poly ADP-ribosylation Reactions; de Murcia, G., Shall, S., Eds; Oxford University Press: Oxford, 2000. Cell Death: The Role of PARP.; Szabo, C., Ed.; CRC Press: Boca Raton, Fl, 2000 and references therein.
3. Griffin, R. J.; Curtin, N. J.; Newell, D. R.; Golding, B. T.; Durkacz B. W.; Calvert, A. H. The role of inhibitors of poly(ADP-ribose) polymerase as resistance-modifying agents in cancer therapy. Biochimie 1995, 77, 408-422.
4. Masutani, M.; Nozaki, T.; Nishiyama, E.; Shimokawa, T.; Tachi, Y.; Suzuki, H.; Nakagama, H.; Wakabayashi, K.; Sigimura, M. Mol. Cell. Biochem. 1999, 193, 149-152. Menissier-de Murcia, J.; Niedergang, C.; Trucco, C.; Ricoul, M.; Ditrillaux, B.; Mark, M.; Olivier, F. J.; Masson, M.; Dierich, A.; LeMeur, M.; Walztinger, C.; Chambon, P.; de Murcia, G. Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 7303-7307. Wang, Z. Q.; Auer, B.; Stingl, L.; Berghammer, H.; Haidacher, D.; Schweiger, M.; Wagner, E. F. Genes Dev. 1995, 9, 509-520.
5. Masutani, M.; Nozaki, T.; Nishiyama, E.; Shimokawa, T.; Tachi, Y.; Suzuki, H.; Nakagama, H.; Wakabayashi, K.; Sigimura, M. Mol. Cell. Biochem. 1999, 193, 149-152. Menissier-de Murcia, J.; Niedergang, C.; Trucco, C.; Ricoul, M.; Ditrillaux, B.; Mark, M.; Olivier, F. J.; Masson, M.; Dierich, A.; LeMeur, M.; Walztinger, C.; Chambon, P.; de Murcia, G. Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 7303-7307. Wang, Z. Q.; Auer, B.; Stingl, L.; Berghammer, H.; Haidacher, D.; Schweiger, M.; Wagner, E. F. Genes Dev. 1995, 9, 509-520.
6. Masutani, M.; Nozaki, T.; Nishiyama, E.; Shimokawa, T.; Tachi, Y.; Suzuki, H.; Nakagama, H.; Wakabayashi, K.; Sigimura, M. Mol. Cell. Biochem. 1999, 193, 149-152. Menissier-de Murcia, J.; Niedergang, C.; Trucco, C.; Ricoul, M.; Ditrillaux, B.; Mark, M.; Olivier, F. J.; Masson, M.; Dierich, A.; LeMeur, M.; Walztinger, C.; Chambon, P.; de Murcia, G. Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 7303-7307. Wang, Z. Q.; Auer, B.; Stingl, L.; Berghammer, H.; Haidacher, D.; Schweiger, M.; Wagner, E. F. Genes Dev. 1995, 9, 509-520.
7. Banasik, M.; Ueda, K. Inhibitors and activators of ADP-ribosylation reactions. Mol. Cell. Biochem. 1994, 138, 185-197.
8. Suto, M. J.; Turner, W. R.; Arundel-Suto, C. M.; Werbel, L. M.; Sebolt-Leopold, J. S. Dihydroisoquinolinones: the design and synthesis of a new series of potent inhibitors of poly(ADP-ribose) polymerase. Anti-Cancer Drug Des. 1991, 7, 107-117.
9. Delaney, C. A.; Wang, L. Z.; Kyle, S.; Srinivasan, S.; White, A. W.; Calvert, A. H.; Curtin, N. J.; Durkacz, B. W.; Hostomsky, Z.; Maegley, K.; Golding, B. T.; Griffin, R. G.; Newell, D. R. Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines. Clin. Cancer Res. 2000, 6, 2860-2867. Bowman, K. J.; Newell, D. R.; Calvert, A. H.; Curtin, N. J. Differential effects of the poly(ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity. Br. J Cancer 2001, 84, 106-112.
10. Delaney, C. A.; Wang, L. Z.; Kyle, S.; Srinivasan, S.; White, A. W.; Calvert, A. H.; Curtin, N. J.; Durkacz, B. W.; Hostomsky, Z.; Maegley, K.; Golding, B. T.; Griffin, R. G.; Newell, D. R. Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines. Clin. Cancer Res. 2000, 6, 2860-2867. Bowman, K. J.; Newell, D. R.; Calvert, A. H.; Curtin, N. J. Differential effects of the poly(ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity. Br. J Cancer 2001, 84, 106-112.
11. White, A. W.; Almassy, R.; Calvert, A. H.; Curtin, N. J.; Griffin, R. J.; Hostomsky, Z.; Maegley, K.; Newell, D. R.; Srinivasan, S.; Golding, B. T. Resistance-modifying agents. 9. Synthesis and biological properties of benzimidazole inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase. J. Med. Chem. 2000, 43, 4084-4097.
12. Maryanoff, B. E.; Ho, W.; McComsey, D. F.; Reitz, A. B.; Grous, P. P.; Nortey, S. O.; Shank, R. P.; Dubinsky, B.; Taylor, R. J., Jr.; Gardocki, J. F. Potential Anxiolytic Agents. Pyrido[1,2-α]-benzimidazoles: A New Structural Class of Ligands for the Benzodiazepine Binding Site on GABA-A Receptors. J. Med. Chem. 1995, 38, 16-20.
13. Kamenka, J. M.; Alam, M. N. Synthesis in series of 6-oxoimidazo-[4,5,1-ij]quinoline. J. Heterocycl. Chem. 1973, 10, 459-462.
14. Kukla, M. J.; Breslin, H. J.; Pauwels, R.; Fedde, C. L.; Miranda, M.; Scott, M. K.; Sherrill, Ronald G.; Raeymaekers, A.; Van Gelder, J.; Andries, L.; Janssen, M. A. C.; De Clerq, R.; Janssen, P. A. J. Synthesis and anti-HIV-1 activity of 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-one (TIBO) derivatives. J. Med. Chem. 1991, 34, 746-751.
15. We were unable to achieve cyclization with aliphatic acid chlorides utilizing method A.
16. Higgins, J.; Marvel, C. S. Benzimidazole polymers from aldehdyes and tetraamines. J. Polym. Sci., Part A-1 1979, 8, 171-177. Austen, S. C.; Kane, J. M. A short synthesis of the PARP inhibitor 2-[4-(trifluoromethyl)phenyl]benzimidazole-4-carboxamide (NU1077). J. Heterocycl. Chem. 2001, 38, 979-980.
17. Higgins, J.; Marvel, C. S. Benzimidazole polymers from aldehdyes and tetraamines. J. Polym. Sci., Part A-1 1979, 8, 171-177. Austen, S. C.; Kane, J. M. A short synthesis of the PARP inhibitor 2-[4-(trifluoromethyl)phenyl]benzimidazole-4-carboxamide (NU1077). J. Heterocycl. Chem. 2001, 38, 979-980.
18. Marx, T.; Breitmaier, E. Chiral porphyrins with menthyl residues attached to carbon. Liebigs Ann. Chem. 1992, 3, 183-185.
19. 50 value of 1.0 means there was no enhancement of the cytotoxicity.
20. Jacobson, E. L.; Jacobson, M. K. Tissue NAD as a biochemical measure of niacin status in humans. Methods Enzymol. 1997, 280, 221-230.
21. Aboul-Ela, N.; Jacobson, E. L.; Jacobson, M. K. Labeling methods for the study of poly- and mono(ADP-ribose) metabolism in cultured cells. Anal. Biochem. 1988, 174, 239-250.